MHRA caution in use alert: lorazepam injection 4mg/mL
28th May 2013
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has issued a caution in use alert for specific batches of lorazepam injection 4mg/mL, 1mL ampoules (Ativan; Pfizer). Although no specific problems have been reported with these batches, glass particles have been identified in a small number of ampoules of subsequent batches (which have not been released). As a precautionary measure and to keep supply of lorazepam injection within circulation, the following procedures should be followed prior to administration:
- all ampoules should be individually checked for particulate matter and not used if found to contain any
- draw up the injection into the syringe via a 5 micron filter needle or filter straw
- replace the filter needle or filter straw with a new sterile needle before administration.
For more information, including the batches affected, see below.
- MHRA infusion device warning with 50mL syringes
- Thalidomide: increased risk of haematological second primary malignancies
- Tolvaptan: risk of liver injury
- MHRA caution in use alert: lorazepam injection 4mg/mL
- Cochrane review: levomepromazine for nausea and vomiting in palliative care
- Cyclizine 50mg/mL injection resolved supply problem
- Sativex reclassified as schedule 4 part 1 Controlled Drug
- Japanese translation of PCF now available!
- Die März/April Ausgabe des APM Newsletter ist fertig
- Buprenorphine therapeutic review